Clinical Trial Update: Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial in HIV-1-infected adults evaluating safety, immunogenicity, and potential efficacy of a vaccine-antibody combination including Ad26.Mos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• HIV Infection

Drugs mentioned

• Ad26.Mos4.HIV (Adenovirus serotype 26 HIV vaccine (Mosaic))
• MVA-BN-HIV
• PGDM1400 (PGDM1400)
• PGT121 (PGT121)
• VRC07-523LS

Snippet

Sponsor: Boris Juelg, MD PhD | Conditions: HIV, Acquired Immunodeficiency Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING